Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777923 | 0.84 | ASIC1 (0.40) | MAPTMEN1KMT2ASMN1; SMN2ASIC1 | |
| SCHEMBL17777971 | 0.82 | KCNK3 (0.39) | KCNK3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17777906 | 0.80 | MET (0.41) | KCNK3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17777763 | 0.78 | ALDH1A1 (0.44) | MAPTMEN1KMT2APTGDR2PKM | |
| SCHEMBL19702816 | 0.75 | PTGDR2 (0.40) | MEN1KMT2ASMN1; SMN2PTGDR2KLK7 | |
| SCHEMBL17777970 | 0.72 | MET (0.41) | KCNK3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17777908 | 0.69 | ASIC1 (0.37) | KCNK3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19711705 | 0.68 | KCNK3 (0.40) | KCNK3MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19702818 | 0.67 | PTGDR2 (0.40) | MEN1KMT2ASMN1; SMN2PTGDR2PTGS2 | |
| SCHEMBL25225321 | 0.66 | MAPT (0.44) | MAPTMEN1KMT2APTGDR2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-10233187-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-03-19 | — | — | US | disclosed |
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2016081918-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | KCNK3 4151/4885MAPT 982/4885MEN1 285/4885 |
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | KCNK3 4151/4885MAPT 982/4885MEN1 285/4885 |
| US-10233187-B2 | Fused bicyclic compounds for the treatment of disease | SLC10A1, VHL, GBA1 | KCNK3 2830/4885MAPT 90/4885MEN1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.